moomoo ID:0
Log Out
  • English
  • 中文繁体
  • 中文简体

MaxCyte (NASDAQ:MXCT) Shares Up 5.8%

Defense World ·  09/22/2022 17:31

MaxCyte, Inc. (NASDAQ:MXCT – Get Rating)'s stock price shot up 5.8% on Tuesday . The stock traded as high as $6.05 and last traded at $6.03. 4,183 shares were traded during mid-day trading, a decline of 99% from the average session volume of 580,017 shares. The stock had previously closed at $5.70.

Analyst Ratings Changes

Separately, BTIG Research lifted their price objective on shares of MaxCyte from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Sunday, August 14th.

Get MaxCyte alerts:

MaxCyte Stock Performance

The firm has a market cap of $621.33 million, a price-to-earnings ratio of -30.50 and a beta of 1.17. The stock's 50 day simple moving average is $5.60.

Insider Buying and Selling at MaxCyte

In other MaxCyte news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of the business's stock in a transaction on Friday, July 1st. The shares were sold at an average price of $4.30, for a total transaction of $13,912,856.40. Following the completion of the sale, the insider now owns 10,735,786 shares in the company, valued at approximately $46,163,879.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.11% of the stock is currently owned by company insiders.

Institutional Trading of MaxCyte

Institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP bought a new stake in shares of MaxCyte in the 2nd quarter worth $27,000. Freemont Management S.A. purchased a new stake in MaxCyte during the first quarter valued at about $68,000. Nkcfo LLC purchased a new stake in MaxCyte during the first quarter valued at about $91,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in MaxCyte during the second quarter valued at about $76,000. Finally, PDT Partners LLC purchased a new stake in MaxCyte during the second quarter valued at about $76,000. Institutional investors own 66.40% of the company's stock.

MaxCyte Company Profile

(Get Rating)

MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Further Reading

  • Get a free copy of the research report on MaxCyte (MXCT)
  • The Worst May be Over for Target, But is the Stock Safe to Buy?
  • Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
  • Two Fun Stocks The Insiders Are Buying
  • Novavax Remains a Risk-On Stock in a Risk-Off Market
  • General Mills: Superior Returns With Less Volatility

Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites and Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.